Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers

This article was originally published in The Gray Sheet

Executive Summary

Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease

You may also be interested in...



Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing

Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year

NEJM Study Deems CRP Significant, Compared With Other Cardiac Markers

A recent New England Journal of Medicine study identifying C-reactive protein as a significant marker of coronary heart disease risk may prove to be a boon for CRP diagnostic manufacturers

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 
UsernamePublicRestriction

Register

MT022401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel